10598512

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAOLD' AT 18:23:42 ON 13 NOV 2008
FILE 'CAOLD' ENTERED AT 18:23:42 ON 13 NOV 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	198.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.84	198.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'REGISTRY' ENTERED AT 18:24:19 ON 13 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2008 HIGHEST RN 1072189-85-5
DICTIONARY FILE UPDATES: 12 NOV 2008 HIGHEST RN 1072189-85-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Updated Search

10598512

```
=>
Uploading C:\Documents and Settings\brobinson1\My Documents\njg,str.str

L9      STRUCTURE UPLOADED

=> s l9
SAMPLE SEARCH INITIATED 18:29:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     6631 TO ITERATE

 30.2% PROCESSED     2000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       127738 TO   137502
PROJECTED ANSWERS:             1 TO      175

L10           1 SEA SSS SAM L9

=> s l9 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 18:29:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   134499 TO ITERATE

100.0% PROCESSED   134499 ITERATIONS                              76 ANSWERS
SEARCH TIME: 00.00.04

L11          76 SEA SSS FUL L9

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                182.04     381.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -1.60

FILE 'HCAPLUS' ENTERED AT 18:29:27 ON 13 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.
```

10598512

FILE COVERS 1907 - 13 Nov 2008 VOL 149 ISS 20
FILE LAST UPDATED: 12 Nov 2008 (20081112/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11
L12 27 L11

=> s l12 and agejas-chicharro, f?/au
3 AGEJAS-CHICHARRO, F?/AU
L13 1 L12 AND AGEJAS-CHICHARRO, F?/AU

=> d l13, ibib abs hitstr, 1

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1103576 HCAPLUS
DOCUMENT NUMBER: 143:386923
TITLE: Preparation of pyridines as mGlu5 receptor antagonists
INVENTOR(S): Agejas-Chicharro, Francisco Javier; Dressman, Bruce Anthony; Gutierrez Sanfeliciano, Sonia; Henry, Steven Scott; Martinez Perez, Jose Antonio; Massey, Steven Marc; Monn, James Allen; Zia-Ebrahimi, Mohammad Sadegh
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005094822	A1	20051013	WO 2005-US7507	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1729771	A1	20061213	EP 2005-724939	20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080194647	A1	20080814	US 2006-598512	20060901

PRIORITY APPLN. INFO.: US 2004-555137P P 20040322
WO 2005-US7507 W 20050309
OTHER SOURCE(S): CASREACT 143:386923; MARPAT 143:386923

GI



I



II

AB The invention is related to compds. I [Ar = (un)substituted Ph, naphthyl; R1 = H, halo, CN, CF3, CO2H and derivs., etc.; R2 = 1,2-ethenediyl, 1,2-ethynediyl], their pharmaceutically acceptable salts, and N-oxides as antagonists of the metabotropic glutamate (mGlu), particularly mGlu5, receptors (no data). I may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor (no data). The invention is also related to the preparation of pyridines I provided they are other than 5-(phenylethynyl)nicotinonitrile. For example, II was prepared, in 56% yield, by Pd-coupling of 3,4-difluoroiodobenzene with 5-ethynylnicotinonitrile. II may be particularly useful for the treatment of anxiety and/or pain.

IT 866683-44-5P, 5-(3-Fluorophenylethynyl)nicotinic acid ethyl ester
866683-53-6P, 3-Bromo-5-(4-fluorophenylethynyl)pyridine
866684-64-2P, 3-Bromo-5-(3-chlorophenylethynyl)pyridine
866684-83-5P, 3-Bromo-5-(3,4-difluorophenylethynyl)pyridine
866686-98-8P, 3-Chloro-5-(4-fluoro-3-nitrophenylethynyl)pyridine
866687-00-5P, [5-(5-Chloropyridin-3-ylethynyl)-2-fluorophenyl]amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyridines as mGlu5 receptor antagonists)

RN 866683-44-5 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[2-(3-fluorophenyl)ethynyl]-, ethyl ester (CA INDEX NAME)



RN 866683-53-6 HCAPLUS
CN Pyridine, 3-bromo-5-[2-(4-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866684-64-2 HCAPLUS
CN Pyridine, 3-bromo-5-[2-(3-chlorophenyl)ethynyl]- (CA INDEX NAME)



RN 866684-83-5 HCAPLUS
CN Pyridine, 3-bromo-5-[2-(3,4-difluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866686-98-8 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(4-fluoro-3-nitrophenyl)ethynyl]- (CA INDEX NAME)



Updated Search

RN 866687-00-5 HCAPLUS
CN Benzenamine, 5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluoro- (CA INDEX NAME)



IT 866685-27-0P, 3-[(4-Fluorophenyl)ethynyl]-5-iodopyridine
866685-33-8P, 3-Bromo-5-(3-fluorophenylethynyl)pyridine
866685-47-4P, 3-Bromo-5-(4-fluorophenylethynyl)pyridine hydrochloride 866685-67-8P, 3-Chloro-5-(3,4-difluorophenylethynyl)pyridine 866685-68-9P, 3-Chloro-5-(4-fluoro-3-methylphenylethynyl)pyridine 866685-75-8P, 3-Chloro-5-(4-fluoro-3-trifluoromethylphenylethynyl)pyridine 866685-76-9P, 3-Chloro-5-(4-fluorophenylethynyl)pyridine 866686-04-6P, 3-[(3-Chlorophenyl)ethynyl]-5-methylsulfanylpyridine hydrochloride 866686-11-5P, 3-[(3-Bromo-4-fluorophenyl)ethynyl]-5-chloropyridine 866686-12-6P, 5-(5-Chloropyridin-3-ylethynyl)-2-fluorobenzamide 866686-14-8P, 5-(5-Chloropyridin-3-ylethynyl)-2-fluoro-N-methylbenzamide 866686-85-3P, 3-Chloro-5-(3-chloro-4-fluorophenylethynyl)pyridine 866686-86-4P, 5-(5-Chloropyridin-3-ylethynyl)-2-fluorobenzonitrile 866687-04-9P, 5-(5-Chloropyridin-3-ylethynyl)-2-fluoro-N,N-dimethylbenzamide hydrochloride 866687-05-0P, N-[5-(5-Chloropyridin-3-ylethynyl)-2-fluorophenyl]acetamide 866687-07-2P, N-[5-(5-Chloropyridin-3-ylethynyl)-2-fluorophenyl]methanesulfonamide 866687-10-7P, 3-Chloro-5-(4-fluoro-3-methoxyphenylethynyl)pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyridines as mGlu5 receptor antagonists)

RN 866685-27-0 HCAPLUS
CN Pyridine, 3-[2-(4-fluorophenyl)ethynyl]-5-iodo- (CA INDEX NAME)



RN 866685-33-8 HCAPLUS
CN Pyridine, 3-bromo-5-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866685-47-4 HCAPLUS
CN Pyridine, 3-bromo-5-[2-(4-fluorophenyl)ethynyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866685-67-8 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(3,4-difluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866685-68-9 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(4-fluoro-3-methylphenyl)ethynyl]- (CA INDEX NAME)



RN 866685-75-8 HCAPLUS
CN Pyridine, 3-chloro-5-[2-[4-fluoro-3-(trifluoromethyl)phenyl]ethynyl]- (CA INDEX NAME)



RN 866685-76-9 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(4-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866686-04-6 HCAPLUS
CN Pyridine, 3-[2-(3-chlorophenyl)ethynyl]-5-(methylthio)-, hydrochloride (1:1) (CA INDEX NAME)



RN 866686-11-5 HCAPLUS
CN Pyridine, 3-[2-(3-bromo-4-fluorophenyl)ethynyl]-5-chloro- (CA INDEX NAME)



RN 866686-12-6 HCAPLUS
CN Benzamide, 5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluoro- (CA INDEX NAME)



RN 866686-14-8 HCAPLUS
CN Benzamide, 5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 866686-85-3 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(3-chloro-4-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 866686-86-4 HCAPLUS
CN Benzonitrile, 5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluoro- (CA INDEX NAME)



RN 866687-04-9 HCAPLUS
CN Benzamide, 5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluoro-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866687-05-0 HCAPLUS
CN Acetamide, N-[5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluorophenyl]- (CA INDEX NAME)



RN 866687-07-2 HCAPLUS
CN Methanesulfonamide, N-[5-[2-(5-chloro-3-pyridinyl)ethynyl]-2-fluorophenyl]- (CA INDEX NAME)



RN 866687-10-7 HCAPLUS
CN Pyridine, 3-chloro-5-[2-(4-fluoro-3-methoxyphenyl)ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 18:08:42 ON 13 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 18:08:51 ON 13 NOV 2008
L1             STRUCTURE UPLOADED
L2               1 S L1
L3              46 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 18:12:39 ON 13 NOV 2008
L4               2 S L3
L5               1 S L4 AND AGEJAS-CHICHARRO, F?/AU
L6               1 S L4 NOT L5
L7               0 S L6 AND DRESSMAN, B?/AU

     FILE 'CAOLD' ENTERED AT 18:13:40 ON 13 NOV 2008
L8               0 S L3

     FILE 'REGISTRY' ENTERED AT 18:24:19 ON 13 NOV 2008
L9               STRUCTURE UPLOADED
L10              1 S L9
L11             76 S L9 FULL

     FILE 'HCAPLUS' ENTERED AT 18:29:27 ON 13 NOV 2008
L12             27 S L11
L13              1 S L12 AND AGEJAS-CHICHARRO, F?/AU

=> s l12 not l13
L14            26 L12 NOT L13

=> s l14 and dressman, b?/au
              27 DRESSMAN, B?/AU
L15            0 L14 AND DRESSMAN, B?/AU

=> s l14 and saneliciano, s?/au
               0 SANELICIANO, S?/AU
L16            0 L14 AND SANELICIANO, S?/AU

=> s l14 and henry, s?/au
             603 HENRY, S?/AU
L17            0 L14 AND HENRY, S?/AU

=> s l14 and perez, j?/au
            3069 PEREZ, J?/AU
L18            0 L14 AND PEREZ, J?/AU

=> d l14, ibib abs hitstr, 1-26

L14  ANSWER 1 OF 26  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:1251984  HCAPLUS
TITLE:                    Direct cationic hair dye compositions comprising a
                          substituted acetylenic carbocyanine derivative
INVENTOR(S):              Lagrange, Alain
```

PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Fr. Demande, 42pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2914855	A1	20081017	FR 2007-54453	20070413
PRIORITY APPLN. INFO.:			FR 2007-54453	20070413

AB Direct cationic hair dye compns. containing a substituted acetylenic carbocyanine derivative are claimed. A hair dye preparation contained 2-(p-diethylaminophenylacetylenyl)pyridinium 0.5%, alkyl polyglucoside 5, PEG-8 6, benzyl alc. 4, hydroxyethyl cellulose 2, buffer pH = 9 50%, and water q.s. 100%.

IT 506438-90-0D, salts
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(direct cationic hair dye compns. comprising substituted acetylenic carbocyanine derivative)

RN 506438-90-0 HCAPLUS

CN Pyridinium, 4-[2-[4-(dimethylamino)-2,3,5,6-tetrafluorophenyl]ethynyl]-2,3,5,6-tetrafluoro-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:770036 HCAPLUS
DOCUMENT NUMBER: 149:104704
TITLE: Preparation of novel 2-amino-5,5-diaryl-imidazol-4-ones for treating cognitive impairment, Alzheimer's disease, neurodegeneration and dementia
INVENTOR(S): Berg, Stefan; Holenz, Joerg; Karlstroem, Sofia; Kihlstroem, Jacob; Lindstroem, Johan; Rakos, Laszlo
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astex Therapeutics Ltd.
SOURCE: PCT Int. Appl., 281pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076046	A1	20080626	WO 2007-SE1119	20071218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080176862	A1	20080724	US 2007-959561	20071219
PRIORITY APPLN. INFO.:			US 2006-870936P	P 20061220
			US 2007-917989P	P 20070515

OTHER SOURCE(S): MARPAT 149:104704
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted Ph, heteroaryl; B = H, halo, CN, (un)substituted Ph, heterocyclyl, heteroaryl, cycloalk(en)yl, alk(en)yl, alk(en)ylcycloalkyl; C = (un)substituted Ph, heteroaryl, heterocyclyl; R1, R2 = OSO2R6; R6 = CF3, NMe2,(un)substituted cyclo/alkyl, (hetero)aryl; R7 = (un)substituted alkyl; m, n = independently 0-1; one of m or n is at least 1; with the exclusion of specified compds.; and their pharmaceutically acceptable salts and solvates], useful in treatment or prophylaxis of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia, were prepared Thus, a multi-step synthesis starting from 2-bromo-1-fluoro-4-iodobenzene was given for II•1/2MeCO2H. II•1/2MeCO2H showed IC50 of 89 nM in TR-FRET assay. Pharmaceutical compns. comprising the compound I alone or in combination with the other therapeutic agent are disclosed.

IT 1035268-77-9P, 4-[(3-Bromophenyl)ethynyl]-2-chloropyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-amino-5,5-diaryl-imidazol-4-ones for treating and preventing cognitive impairment, Alzheimer's disease, neurodegeneration and dementia)

RN 1035268-77-9 HCAPLUS

CN Pyridine, 4-[2-(3-bromophenyl)ethynyl]-2-chloro- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:383636 HCAPLUS
DOCUMENT NUMBER: 146:401967
TITLE: Preparation of tetracyclic inhibitors of Janus kinases
INVENTOR(S): Arvanitis, Argyrios G.; Rodgers, James D.; Combs, Andrew P.; Sparks, Richard B.; Robinson, Darius J.; Fridman, Jordan S.; Vaddi, Krishna
PATENT ASSIGNEE(S): Incyte Corporation, USA
SOURCE: PCT Int. Appl., 148pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007038215	A1	20070405	WO 2006-US36872	20060921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2621261	A1	20070405	CA 2006-2621261	20060921
US 20070149506	A1	20070628	US 2006-524641	20060921
EP 1926735	A1	20080604	EP 2006-825052	20060921
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:	US 2005-719462P	P	20050922
	US 2006-810490P	P	20060602
	WO 2006-US36872	W	20060921

OTHER SOURCE(S): MARPAT 146:401967
GI



I



II



III



IV

AB The invention is related to tetracyclic compds. I, II, and III [D1-D7 = independently CR1, N; E = O, S, SO, SO2, NH and derivs.; G = N, CH and derivs.; Q1, Q2 = independently H, NH and derivs.; W = -W1-W2-W3-W4; W1 = absent, O, S, NH and derivs., SO2, NHCONH and derivs., alkyl, etc.; W2 = absent, (un)substituted alk(en/yn)yl, (hetero)aryl, etc.; W3 = absent, :N, :NO, alkoxy, CONH and derivs., SONH and derivs., (un)substituted alk(en/yn)yl, etc.; W4 = H, CN, NH2 and derivs., (un)substituted cyclo/alkyl, heterocycloalkyl, etc.; provided that when D7 = N, E = O, S; and G = N, then W is other than H] and their pharmaceutically acceptable salts or prodrugs, that modulate, especially inhibit, the activity of Janus kinases. Thus, IV was prepared by a general procedure. Selected tetracyclic compds. I-III showed an IC50 of 10μM or less for the inhibition of JAK1 and/or JAK2, and/or JAK3 in an in vitro assay. Thus, I-III are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

IT 933768-07-1P, 2-Fluoro-3-[(4-fluoro-2-nitrophenyl)ethynyl]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tetracyclic inhibitors of Janus kinases)

RN 933768-07-1 HCAPLUS

CN Pyridine, 2-fluoro-3-[2-(4-fluoro-2-nitrophenyl)ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1330282 HCAPLUS
DOCUMENT NUMBER: 147:486182
TITLE: One-shot double elimination process: a practical and concise protocol for diarylacetylenes
AUTHOR(S): Orita, Akihiro; Taniguchi, Hisataka; Otera, Junzo
CORPORATE SOURCE: Department of Applied Chemistry, Okayama University of Science, Ridai-cho, Okayama, 700-0005, Japan
SOURCE: Chemistry--An Asian Journal (2006), 1(3), 430-437
CODEN: CAAJBI; ISSN: 1861-4728
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:486182

AB A variety of diarylacetylenes were obtained in good yields when lithium hexamethyldisilazide was added to a solution of aryl Me sulfone, aryl aldehyde, and di-Et chlorophosphate in THF. In this one-shot process, a number of transformations such as aldol reaction, phosphorylation of aldolate, and double elimination of the resulting β-substituted sulfone proceeded successively to afford the desired acetylenes. The one-shot process was accelerated by the substitution of halogen atoms on the Ph groups, and unsym. substituted diarylacetylenes were obtained without contamination of the dehalogenated products. Diarylacetylenes with other substituents such as CF3, CO2Et, NMe2, C.tplbond.CSiMe3 as well as pyridinyl and thienyl moieties were also accessible with this method. However, methoxy-substituted compds. were obtained in moderate yields under the same conditions, but the yields were increased when lithium diisopropylamide was used instead.

IT 954108-66-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of diarylacetylenes from sulfone, aldehyde and chlorophosphate)

RN 954108-66-8 HCAPLUS
CN Pyridine, 2-bromo-6-[2-(3-bromophenyl)ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1091814 HCAPLUS
DOCUMENT NUMBER: 146:462104
TITLE: Polyhaloheterocyclic compounds. Part 53. Sonogashira reactions of 2,4,6-tribromo-3,5-difluoropyridine
AUTHOR(S): Benmansour, Hadjar; Chambers, Richard D.; Sandford, Graham; Yufit, Dmitrii S.; Howard, Judith A. K.

CORPORATE SOURCE: Department of Chemistry, University of Durham, Durham, DH1 3LE, UK
SOURCE: ARKIVOC (Gainesville, FL, United States) (2007), (11), 46-55
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2007/HG-2110EP%20as%20published%20mainmanuscript.pdf
PUBLISHER: Arkat USA Inc.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:462104
GI



AB Palladium-catalyzed Sonogashira reactions between 2,4,6-tribromo-3,5-difluoropyridine and a variety of phenylacetylene derivs. gave 4-bromo-2,6-bis(2-phenylethynyl)-3,5-difluoropyridines (I; R = H, 4-MeO, 4-F, 2-Cl, 4-Cl, 4-Br).
IT 935395-86-1P 935395-87-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(bis(arylethynyl)bromodifluoropyridines via palladium complex catalyzed Sonogashira coupling of tribromodifluoropyridine with arylacetylenes)
RN 935395-86-1 HCAPLUS
CN Pyridine, 4-bromo-2,6-bis[2-(4-chlorophenyl)ethynyl]-3,5-difluoro- (CA INDEX NAME)



RN 935395-87-2 HCAPLUS
CN Pyridine, 4-bromo-2,6-bis[2-(4-bromophenyl)ethynyl]-3,5-difluoro- (CA INDEX NAME)



IT 935395-84-9P 935395-85-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure; bis(arylethynyl)bromodifluoropyridines via palladium complex catalyzed Sonogashira coupling of tribromodifluoropyridine with arylacetylenes)
RN 935395-84-9 HCAPLUS
CN Pyridine, 4-bromo-3,5-difluoro-2,6-bis[2-(4-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 935395-85-0 HCAPLUS
CN Pyridine, 4-bromo-2,6-bis[2-(2-chlorophenyl)ethynyl]-3,5-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1155535 HCAPLUS
DOCUMENT NUMBER: 143:422040
TITLE: Diarylalkyne compounds with MCH-receptor antagonistic activity, their preparation, pharmaceutical compositions, and use in therapy
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 62 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050239826	A1	20051027	US 2005-104915	20050413
DE 102004017935	A1	20051103	DE 2004-102004017935	20040414
CA 2559021	A1	20051103	CA 2005-2559021	20050408
WO 2005103031	A1	20051103	WO 2005-EP3683	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1740572	A1	20070110	EP 2005-716558	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007532593	T	20071115	JP 2007-507706	20050408

PRIORITY APPLN. INFO.:

DE 2004-102004017935A		20040414
US 2004-563677P	P	20040420
WO 2005-EP3683	W	20050408

10598512

OTHER SOURCE(S): CASREACT 143:422040; MARPAT 143:422040
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to alkyne compds. of general formula I, which are antagonists of melanin-concentrating hormone (MCH) receptors. In compds. I, R1 is selected from C3-6 alkenyl, C3-6 alkynyl, (hydroxy-C3-7 cycloalkyl)-C1-3 alkyl, oxa-C4-7 cycloalkyl, and dihydroxy-C3-7 alkyl, each optionally substituted; R2 is independently selected from H, (un)substituted C1-8 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc., or R1 and R2, together with the N atom to which they are bound, form an (un)substituted heterocycle; X is (un)substituted C1-4 alkylene; W and Z are each independently a bond or a C1-2 alkylene; Y and A are each independently (un)substituted Ph, (un)substituted pyridinyl, (un)substituted pyrimidinyl, (un)substituted pyrazinyl, etc.; B is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc.; including tautomers, enantiomers, salts, and mixts. thereof, with 6 specific compds. excluded. The invention also relates to the preparation of I, pharmaceutical compns. containing I and one or more physiol. acceptable excipients, inert carriers or diluents, as well as to the use of the compns. for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes. N-Alkylation of 3-methylpyridine with benzyl chloride followed by hydride reduction, asym. dihydroxylation, and debenzylation gave optically active piperidinediol II. 2-Bromoethanol underwent substitution with 4-iodo-2-methylphenol to give the corresponding ether, which was coupled with trimethylsilylacetylene and desilylated to give alkyne III. Coupling of III with 2,5-dibromopyridine, Suzuki coupling with 4-chlorophenylboronic acid, mesylation and substitution with piperidinediol II resulted in the formation of diarylalkyne IV. The compds. of the invention are MCH-receptor antagonists, with compound IV expressing an IC50 value of 10.9 nM.

IT 1056986-35-6 1056986-36-7 1056986-37-8
1056986-38-9 1056986-39-0 1056986-40-3
1056986-41-4
RL: PRPH (Prophetic)
(Diarylalkyne compounds with MCH-receptor antagonistic activity, their preparation, pharmaceutical compositions, and use in therapy)

RN 1056986-35-6 HCAPLUS

CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-36-7 HCAPLUS
CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-37-8 HCAPLUS
CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-ethyl-, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-38-9 HCAPLUS
CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-ethyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-39-0 HCAPLUS
CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-40-3 HCAPLUS
CN 3,4-Piperidinediol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056986-41-4 HCAPLUS
CN 1,3-Propanediol, 2-[[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]amino]- (CA INDEX NAME)



IT 866928-79-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diarylalkynes as MCH-receptor antagonists)
RN 866928-79-2 HCAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 866929-99-9P, 2-[2-Bromo-4-[5-(4-chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethanol 866930-00-9P, 2-[2-Bromo-4-[5-(4-chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethyl methanesulfonate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of diarylalkynes as MCH-receptor antagonists)
RN 866929-99-9 HCAPLUS
CN Ethanol, 2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]- (CA INDEX NAME)



RN 866930-00-9 HCAPLUS
CN Ethanol, 2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]-, 1-methanesulfonate (CA INDEX NAME)



L14 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1132924 HCAPLUS
DOCUMENT NUMBER: 143:405812
TITLE: Preparation of substituted pyridine alkynes with MCH antagonistic activity for the treatment of metabolic disorders
INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Rudolf, Klaus; Schindler, Marcus; Thomas, Leo; Lotz, Ralf
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050234101	A1	20051020	US 2005-104889	20050413
DE 102004017934	A1	20051103	DE 2004-102004017934	20040414
CA 2559688	A1	20051103	CA 2005-2559688	20050408
WO 2005103002	A2	20051103	WO 2005-EP3685	20050408
WO 2005103002	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,

SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1737823 A2 20070103 EP 2005-737015 20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2007532595 T 20071115 JP 2007-507708 20050408
PRIORITY APPLN. INFO.: DE 2004-102004017934A 20040414
US 2004-563590P P 20040420
WO 2005-EP3685 W 20050408
OTHER SOURCE(S): CASREACT 143:405812
GI



II

AB Various substituted pyridinyl alkynes are prepared For instance, 2-[[4-[[5-(4-chlorophenyl)pyridin-2-yl]ethynyl]-2-methylphenyl]oxy]ethyl methanesulfonate (I) is prepared in 6 steps from 4-iodophenol, 2-bromoethanol, trimethylsilylacetylene, 2,5-dibromopyridine and 4-chlorophenylboronic acid. This intermediate is reacted with a variety of amines to produce example compds. I is converted to II by displacement with the corresponding amine. II exhibits an IC50 = 6.2 nM for MCH-1. Example compds. are useful for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

IT 866928-78-1P 866928-79-2P 866928-80-5P
866928-81-6P 866928-82-7P 866928-83-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 866928-78-1 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-79-2 HCAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-80-5 HCAPLUS
CN Pyridine, 2-[2-[3-bromo-4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-81-6 HCAPLUS
CN 4-Piperidinol, 1-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (CA INDEX NAME)



RN 866928-82-7 HCAPLUS
CN Pyridine, 2-[2-[3-bromo-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (CA INDEX NAME)



RN 866928-83-8 HCAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



IT 866929-99-9P, 2-[2-Bromo-4-[5-(4-chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethanol 866930-00-9P, 2-[2-Bromo-4-[5-(4-chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethyl methanesulfonate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 866929-99-9 HCAPLUS
CN Ethanol, 2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]- (CA INDEX NAME)



RN 866930-00-9 HCAPLUS
CN Ethanol, 2-[2-bromo-4-[2-[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]-, 1-methanesulfonate (CA INDEX NAME)



L14 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:479549 HCAPLUS
DOCUMENT NUMBER: 143:172503
TITLE: Supramolecular Nano Networks Formed by Molecular-Recognition-Directed Self-Assembly of Ditopic Calix[5]arene and Dumbbell [60]Fullerene
AUTHOR(S): Haino, Takeharu; Matsumoto, Youko; Fukazawa, Yoshimasa
CORPORATE SOURCE: Department of Chemistry, Graduate School of Science, Hiroshima University, Higashi-Hiroshima, 739-8526, Japan
SOURCE: Journal of the American Chemical Society (2005), 127(25), 8936-8937
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:172503

AB Dumbbell fullerene and ditopic bisdouble-calix[5]arene were synthesized. Their iterative host-guest complexations create the supramol. nano network. SEM revealed the formation of the branched fiber, possessing a length of >100 μm and widths of 250-500 nm on a glass plate. More detailed information was given by atomic force microscopy. The formed fibers on a mica plate have widths of 60-90 nm and heights of 1.2-1.9 nm. The nanosize assemblies are probably composed of a bundle of 40-60 polymer chains created by entangling the alkyl side chains with van der Waals interaction.

IT 861108-92-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(hydrolysis; supramol. nano networks formed by mol.-recognition-directed self-assembly of ditopic calix[5]arene and dumbbell C60)
RN 861108-92-1 HCAPLUS
CN 2,6-Pyridinedicarboxylic acid, 4-[2-[2,5-bis(dodecyloxy)-4-iodophenyl]ethynyl]-, 2,6-dimethyl ester (CA INDEX NAME)



IT 861108-93-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(supramol. nano networks formed by mol.-recognition-directed self-assembly of ditopic calix[5]arene and dumbbell C60)
RN 861108-93-2 HCAPLUS
CN 2,6-Pyridinedicarboxylic acid, 4-[2-[2,5-bis(dodecyloxy)-4-iodophenyl]ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:177838 HCAPLUS
DOCUMENT NUMBER: 142:280057
TITLE: Preparation of substituted pyridinones as modulators of p38 MAP kinase
INVENTOR(S): Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.; Blevis-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott, Ian L.; Mcgee, Kevin F.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 968 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018557	A2	20050303	WO 2004-US26193	20040813
WO 2005018557	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1026826	A1	20050216	NL 2004-1026826	20040812
NL 1026826	C2	20070104		
US 20050176775	A1	20050811	US 2004-918826	20040813

PRIORITY APPLN. INFO.: US 2003-494959P P 20030813
OTHER SOURCE(S): MARPAT 142:280057
GI



I



II

AB Disclosed are title compds. I and their pharmaceutically acceptable salts [R1 H, halo, NO2, CHO, CN, (un)substituted hydroxy/dihydroxy/aryl/alkyl, etc.; R2 = H, OH, halo, (un)substituted alkyl, alkoxy, etc.; R3 = H, halo, (un)substituted aryl/alkoxycarbonyl, arylalkyl, arylthio, etc.; R4 = H, (un)substituted alkyl; R5 = H, aryl, arylalkyl, etc.]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compns. containing the compds., methods of preparing the compds. and methods of treatment using the compds. are also disclosed. For example, II was prepared, in 3 steps, reacting 4-hydroxy-6-methylpyrone with NH4OH, followed by O-alkylation with 2,4-difluorobenzyl chloride, and bromination with Br2 in AcOH/H2O. Selected I inhibited MKK6-activated human p38α kinase phosphorylation of a biotinylated substrate or human p38α-induced phosphorylation of EGFRP (epidermal growth factor receptor peptide) with an IC50 in the range of 1 μM to 25 μM.

IT 586378-85-0P, 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

RN 586378-85-0 HCAPLUS

CN 2(1H)-Pyridinone, 3-bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
RN 586386-30-3 HCAPLUS
CN 2(1H)-Pyridinone, 3-bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethynyl]-6-methyl- (CA INDEX NAME)



L14 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:996178 HCAPLUS
DOCUMENT NUMBER: 141:424170
TITLE: Azaindole compounds as Janus kinase 3 (JAK3 kinase) inhibitors, and their preparation, intermediates, and pharmaceutical compositions
INVENTOR(S): David, Laurent; Hansen, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099205	A1	20041118	WO 2004-SE696	20040506

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004236146	A1	20041118	AU 2004-236146		20040506
AU 2004236146	B2	20071213			
CA 2523922	A1	20041118	CA 2004-2523922		20040506
EP 1625127	A1	20060215	EP 2004-731527		20040506
EP 1625127	B1	20070523			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004010117	A	20060523	BR 2004-10117		20040506
CN 1784403	A	20060607	CN 2004-80012626		20040506
JP 2006525998	T	20061116	JP 2006-508046		20040506
AT 362932	T	20070615	AT 2004-731527		20040506
ES 2286634	T3	20071201	ES 2004-731527		20040506
IN 2005DN04779	A	20071207	IN 2005-DN4779		20051019
MX 2005PA12026	A	20060203	MX 2005-PA12026		20051108
US 20060287354	A1	20061221	US 2005-556227		20051109
PRIORITY APPLN. INFO.:			SE 2003-1372	A	20030509
			WO 2004-SE696	W	20040506

OTHER SOURCE(S): MARPAT 141:424170

GI



AB The invention relates to novel azaindole compds. I. which are kinase inhibitors, specifically of Janus kinase 3, also known as JAK3 kinase. The invention also relates to methods and intermediates for preparation of I, and pharmaceutical compns. comprising I. In compds. I, Ar is Ph which can be optionally substituted by one or more groups selected from halo, OH, cyano, C1-C8 alkyl (itself optionally substituted by one or more OH or cyano groups or F atoms), CH2R2, CH2O(CH2)nO(C1-6-alkyl), or (C1-C8-alkyl)NR3R4; R2 is a 5- to 7-membered saturated ring containing 1 or 2 N/O/S heteroatoms, an aryl or a 5- to 7-membered heteroaryl containing 1-3 N/O/S heteroatoms, all of these being optionally substituted by one or more OH or CH2OH groups; R3 is H or C1-6 alkyl; and R4 is C1-6 alkyl

optionally substituted by one or more groups OH or Ph; n is 1-4; R1 is H or Ph optionally substituted by halo, C1-C8 alkoxy, C1-C8 thioalkyl, or C1-C8 alkyl; and pharmaceutically acceptable salts thereof. Nineteen compds. I were prepared, some as trifluoroacetate salts, and these same compds. are all claimed individually as the free bases. For instance, 6-amino-4-methoxynicotinic acid Me ester was subjected to a sequence of: (1) electrophilic iodination in the 5-position, (2) alkyne coupling of the iodide with HC.tplbond.CC6H4F-4, (3) base-catalyzed cyclization of the alkyne adduct to give a pyrrolopyridine ring, (4) acidic saponification of the ester and demethylation of the methoxy group with HBr, (5) chlorination of the resultant hydroxy group and acid using POCl3, with ammonolysis of the acid chloride, and (6) amination of the ring chloride with 2-ethylaniline, to give invention compound II. In a JAK3 HTRF assay, the example compds. had IC50 values less than 25 μM.

IT 796032-89-8P, 6-Amino-5-[(4-fluorophenyl)ethynyl]-4-methoxynicotinic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azaindole derivs. as JAK3 kinase inhibitors)

RN 796032-89-8 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-amino-5-[2-(4-fluorophenyl)ethynyl]-4-methoxy-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:604339 HCAPLUS

DOCUMENT NUMBER: 141:277462

TITLE: Synthesis, optical properties, crystal structures and phase behaviour of selectively fluorinated 1,4-bis(4'-pyridylethynyl)benzenes, 4-(phenylethynyl)pyridines and 9,10-bis(4'-pyridylethynyl)anthracene, and a Zn(NO3)2 coordination polymer

AUTHOR(S): Fasina, Tolulope M.; Collings, Jonathan C.; Lydon, Donocadh P.; Albesa-Jove, David; Batsanov, Andrei S.; Howard, Judith A. K.; Nguyen, Paul; Bruce, Mitch; Scott, Andrew J.; Clegg, William; Watt, Stephen W.; Viney, Christopher; Marder, Todd B.

CORPORATE SOURCE: Department of Chemistry, University of Durham, Durham, DH1 3LE, UK

SOURCE: Journal of Materials Chemistry (2004), 14(15),

2395-2404
CODEN: JMACEP; ISSN: 0959-9428
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:277462

AB Selectively fluorinated and nonfluorinated rigid rods based on the 4-pyridylethynyl group, 1,4-bis(4'-pyridylethynyl)benzene (1a), 1,4-bis(4'-pyridylethynyl)tetrafluorobenzene (1b), 1,4-bis(2',3',5',6'-tetrafluoropyridylethynyl)benzene (1c), 1,4-bis(2',3',5',6'-tetrafluoropyridylethynyl)tetrafluorobenzene (1d), 9,10-bis(4'-pyridylethynyl)anthracene (2), 4-(pentafluorophenylethynyl)pyridine (3a) and 4-(phenylethynyl)tetrafluoropyridine (3b) were prepared in good yields using Pd/Cu-catalyzed Sonogashira cross-coupling reactions and/or Li chemical involving nucleophilic aromatic substitution. UV-visible absorption and fluorescence spectra for 1a-d and 2 are reported. The x-ray crystal structures of 1b, 1c, 2, 3a and 3b show a variety of packing motifs, none of which involve arene-perfluoroarene stacking. The phase behavior of 1a-1c was studied by DTA and transmitted polarized light microscopy. 1B exhibits an ordered phase from 227.6 to 272.5° which is either hexatic B or crystal B. A 1:1 complex (4) between 1b and Zn(NO3)2 was prepared; its crystal structure consists of zigzag polymer chains held together by H bonds.

IT 760981-37-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and luminescence spectra)

RN 760981-37-1 HCAPLUS

CN Pyridine, 4,4'-[(2,3,5,6-tetrafluoro-1,4-phenylene)di-2,1-ethynediyl]bis[2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:70323 HCAPLUS
DOCUMENT NUMBER: 140:253552
TITLE: Synthesis and light-emitting characteristics of doughnut-shaped π-electron systems
AUTHOR(S): Yamaguchi, Yoshihiro; Kobayashi, Shigeya; Miyamura, Satoshi; Okamoto, Yoshifumi; Wakamiya, Tateaki; Matsubara, Yoshio; Yoshida, Zen-ichi
CORPORATE SOURCE: Faculty of Science and Engineering, Kinki University, Higashi-Osaka, Osaka, 577-8502, Japan

SOURCE: Angewandte Chemie, International Edition (2004), 43(3), 366-369
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:253552
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Highly sym., functionally and structurally interesting doughnut-shaped octakis-m-cyclynes I and similar octakis-p-cyclynes were synthesized and shown to be a new class of light-emitting fluorescent materials. A pentacoordinate CuII complex of I (R = MeO2C) exhibits remarkably intense fluorescence, contrary to the behavior expected for CuII complexes, which suggests that other transition-metal complexes of I may also function as luminescent materials.

IT 669063-99-4P 669064-01-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and light-emitting characteristics of doughnut-shaped octakis(cyclynes) and their complexes)

RN 669063-99-4 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[[4-[[6-[(4-iodophenyl)ethynyl]-4-(methoxycarbonyl)-2-pyridinyl]ethynyl]phenyl]ethynyl]-6-[(trimethylsilyl)ethynyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 669064-01-1 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-ethynyl-6-[[4-[[6-[(4-iodophenyl)ethynyl]-4-(methoxycarbonyl)-2-pyridinyl]ethynyl]phenyl]ethynyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:656582 HCAPLUS
DOCUMENT NUMBER: 139:197371
TITLE: Preparation of substituted pyridinones as modulators of p38 MAP kinase
INVENTOR(S): Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.; Blevis-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott, Ian L.; McGee, Kevin F.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 1052 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068230	A1	20030821	WO 2003-US4634	20030214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476012	A1	20030821	CA 2003-2476012	20030214
AU 2003217433	A1	20030904	AU 2003-217433	20030214

US 20040058964	A1	20040325	US 2003-367987		20030214
US 7067540	B2	20060627			
BR 2003007631	A	20041221	BR 2003-7631		20030214
EP 1490064	A1	20041229	EP 2003-713478		20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1646125	A	20050727	CN 2003-808042		20030214
JP 2005531501	T	20051020	JP 2003-567412		20030214
JP 4164031	B2	20081008			
NZ 534395	A	20061027	NZ 2003-534395		20030214
IN 2004DN02150	A	20050401	IN 2004-DN2150		20040723
MX 2004PA07470	A	20041110	MX 2004-PA7470		20040802
ZA 2004006275	A	20051004	ZA 2004-6275		20040805
NO 2004003820	A	20041109	NO 2004-3820		20040913
US 20060211694	A1	20060921	US 2005-226556		20050914
US 20070088033	A1	20070419	US 2006-531492		20060913
JP 2007023053	A	20070201	JP 2006-263778		20060928
KR 2007017443	A	20070209	KR 2007-701895		20070125
AU 2007202607	A1	20070628	AU 2007-202607		20070607
PRIORITY APPLN. INFO.:			US 2002-357029P	P	20020214
			US 2002-436915P	P	20021230
			AU 2003-217433	A3	20030214
			JP 2003-567412	A3	20030214
			US 2003-367987	A1	20030214
			WO 2003-US4634	W	20030214
			KR 2004-712622	A3	20040813
			US 2005-226556	A3	20050914

OTHER SOURCE(S): MARPAT 139:197371
GI



I



II

AB Disclosed are title compds. I [wherein R1 = H, halo, NO2, CHO, CN, CO2H, or (un)substituted (halo)alkyl, (aryl)alkoxy, aryl(alkyl), alkenyl, (aryl)alkynyl, (aryl)alkanoyl, alkoxyalkyl, or haloalkoxy; R2 = H, OH, halo, NR8R9, CO2R, or (un)substituted OSO2-alkyl, OSO2-aryl, arylalkoxy, aryloxy(alkyl), arylthio(alkoxy), arylalkynyl, alkoxy(alkoxy), alkyl, alkynyl, OCONH(CH2)n-aryl, OCON(alkyl)(CH2)n-aryl, dialkylamino, (hetero)aryl(alkyl), arylalkenyl, or heterocycloalkyl(alkyl); R3 = H, halo, alkenyl, NR6R7, NR6R7-alkyl, alkyl, or (un)substituted (aryl)alkoxycarbonyl, aryloxycarbonyl, arylalkyl, OCONH(CH2)n-aryl, arylalkoxy, OCON(alkyl)(CH2)n-aryl, aryloxy, arylthio, or (aryl)thioalkoxy; R4 = H or (un)substituted alkyl; R5 = H, aryl, aryl(thio)alkyl, NH2, alkoxycarbonyl, alkynyl, SO2-alkyl,

(hetero)cycloalkyl(alkyl), heteroaryl, or (un)substituted alkyl, alkoxy(alkyl), or alkenyl; R6 and R7 = independently H, OH, or (un)substituted (aryl)alkyl, alkoxy(alkyl), alkanoyl(alkyl), arylalkoxy, SO2-alkyl, (aryl)alkoxycarbonyl, heteroarylalkyl, or arylalkanoyl; or NR6R7 = (un)substituted (thio)morpholinyl, pyrrolidinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R8 = independently H or (un)substituted (aryl)alkyl or (aryl)alkanoyl; R9 = H or (un)substituted (aryl)alkyl, (aryl)alkanoyl, cycloalkyl(alkyl), alkenyl, heteroaryl, (alkyl)aminoalkyl, SO2Ph, or aryl; R = independently H or (un)substituted alkyl; n = 0-6; and pharmaceutically acceptable salts thereof]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity, such as inflammation, ischemia, viral infections, and autoimmune diseases (no data). Pharmaceutical compns. containing I, methods of preparing them, and methods of treatment using the compds. are also disclosed. For example, reaction of 4-benzyloxy-2(1H)-pyridone with EtBr in the presence of K2CO3 in DMF gave II. The latter inhibited MKK6-activated human p38α kinase phosphorylation of a biotinylated substrate or human p38α-induced phosphorylation of EGFRP (epidermal growth factor receptor peptide) with an IC50 in the range of 1 μM to 25 μM.

IT 586378-85-0P, 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

RN 586378-85-0 HCAPLUS

CN 2(1H)-Pyridinone, 3-bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

RN 586386-30-3 HCAPLUS

CN 2(1H)-Pyridinone, 3-bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethynyl]-6-methyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2003:385603 HCAPLUS
DOCUMENT NUMBER:	139:149513
TITLE:	Shape-Persistent Macrocycles with Terpyridine Units: Synthesis, Characterization, and Structure in the Crystal
AUTHOR(S):	Grave, Christian; Lentz, Dieter; Schaefer, Andreas; Samori, Paolo; Rabe, Juergen P.; Franke, Peter; Schlueter, A. Dieter
CORPORATE SOURCE:	Institut fuer Chemie, Freie Universitaet Berlin, Berlin, D-14195, Germany
SOURCE:	Journal of the American Chemical Society (2003), 125(23), 6907-6918 CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 139:149513
GI	

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The synthesis of a variety of shape-persistent macrocycles with either one or two opposing terpyridine units and inner diams. of up to 2 nm is described. The sequences are mainly based on transition metal cross-coupling reactions and, whenever appropriate, compared with one another regarding their resp. efficiency. Typical overall yields and amts. prepared range from 8% to 27% and 25 mg to 290 mg. For solubility and processing of the targeted cycles, all precursors were equipped with flexible side chains (hexyloxy or hexyloxymethyl). Characterization of the products is based on MALDI-TOF mass spectrometry, 2D NMR spectroscopy, and/or low-temperature single-crystal X-ray diffraction. Their packing in the crystal is discussed in terms of both number and length of side chains. Cycle I was physisorbed into an ordered structure at the solution-HOPG interface and investigated by scanning tunneling microscopy (STM).

IT 569672-29-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, characterization, and crystal structure of shape-persistent macrocycles with terpyridine units)
RN 569672-29-3 HCAPLUS
CN Pyridine, 2-bromo-5-[2-[3-bromo-5-(hexyloxy)phenyl]ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 105 THERE ARE 105 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:893916 HCAPLUS
DOCUMENT NUMBER: 138:294508
TITLE: Molecular design on substituted DAST derivatives for second-order nonlinear optics
AUTHOR(S): Umezawa, Hirohito; Tsuji, Kyoko; Okada, Shuji; Oikawa, Hidetoshi; Matsuda, Hiro; Nakanishi, Hachiro
CORPORATE SOURCE: Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
SOURCE: Optical Materials (Amsterdam, Netherlands) (2003), 21(1-3), 75-78
CODEN: OMATET; ISSN: 0925-3467
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mol. design of the derivs. of 1-methyl-4-(2-(4-(dimethylamino)phenyl)ethynyl)pyridinium (DAS) was investigated from the following two points, i.e., simple substitution of one aromatic hydrogen atom to enhance hyperpolarizability β and fluorine substitution to decrease optical loss due to overtones of C-H bond vibration. By the screening using semiempirical calcn., 2-cyano-1-methyl-4-(2-(4-(dimethylamino)phenyl)ethynyl)pyridinium 7, 2,3,5,6-tetrafluoro-1-methyl-4-(2-(4-(dimethylamino)-2,3,5,6-tetrafluorophenyl)ethynyl)pyridinium 10, etc. were expected to have larger β than that of DAS. The salts of 7 and 1-methyl-4-(2-(4-(dimethylamino)-2,3,5,6-tetrafluorophenyl)ethynyl)pyridinium as a related cation of 10 were synthesized and four crystals showing second-harmonic generation were found.
IT 506438-90-0
RL: PRP (Properties)
(mol. design on substituted DAST derivs. for second-order nonlinear optics)
RN 506438-90-0 HCAPLUS
CN Pyridinium, 4-[2-[4-(dimethylamino)-2,3,5,6-tetrafluorophenyl]ethynyl]-2,3,5,6-tetrafluoro-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:736252 HCAPLUS
DOCUMENT NUMBER: 137:263031
TITLE: Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors
INVENTOR(S): Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074767	A1	20020926	WO 2002-SE472	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440630	A1	20020926	CA 2002-2440630	20020313
AU 2002237626	A1	20021003	AU 2002-237626	20020313
AU 2002237626	B2	20070517		
EE 200300445	A	20031215	EE 2003-445	20020313
EP 1370556	A1	20031217	EP 2002-704031	20020313
EP 1370556	B1	20060719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008104	A	20040302	BR 2002-8104	20020313
CN 1509272	A	20040630	CN 2002-809788	20020313
CN 1304377	C	20070314		
CN 1509286	A	20040630	CN 2002-809915	20020313
CN 1509276	A	20040630	CN 2002-810093	20020313

CN 1269804	C	20060816			
JP 2004527515	T	20040909	JP 2002-573776		20020313
HU 2004000327	A2	20050128	HU 2004-327		20020313
HU 2004000327	A3	20050628			
NZ 528106	A	20050324	NZ 2002-528106		20020313
EP 1676846	A2	20060705	EP 2006-8158		20020313
EP 1676846	A3	20060726			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AT 333454	T	20060815	AT 2002-704031		20020313
RU 2288228	C2	20061127	RU 2003-127734		20020313
ES 2267986	T3	20070316	ES 2002-704031		20020313
CN 1962641	A	20070516	CN 2006-10106152		20020313
IN 2003MN00805	A	20050318	IN 2003-MN805		20030827
ZA 2003006731	A	20041129	ZA 2003-6731		20030828
ZA 2003006732	A	20041129	ZA 2003-6732		20030828
ZA 2003006734	A	20041129	ZA 2003-6734		20030828
ZA 2003006737	A	20041129	ZA 2003-6737		20030828
MX 2003PA08191	A	20040129	MX 2003-PA8191		20030910
NO 2003004045	A	20031110	NO 2003-4045		20030912
US 20040127528	A1	20040701	US 2004-471900		20040114
US 7427631	B2	20080923			
HK 1059932	A1	20061222	HK 2004-102796		20040421
US 20080171882	A1	20080717	US 2007-928040		20071030
PRIORITY APPLN. INFO.:			SE 2001-902	A	20010315
			CN 2002-810093	A3	20020313
			EP 2002-704031	A3	20020313
			WO 2002-SE472	W	20020313
			US 2004-471900	A1	20040114

OTHER SOURCE(S): MARPAT 137:263031

GI



I



II

AB The title compds. [I; X = NR1, O, S; Y1, Y2 = O, S; Z = SO, SO2; m = 1, 2; A = a bond, alkyl, haloalkyl, etc.; R1 = H, alkyl, haloalkyl; R2, R3 = H,

halo, alkyl, etc.; R4 = H, halo, alkyl, haloalkyl; R5 = monocyclic, bicyclic or tricyclic group selected from (un)substituted cycloalkyl, aryl, heterocycloalkyl, heteroaryl], useful as metalloproteinase inhibitors, especially as inhibitors of MMP12, were prepared Thus, reacting 1-[4-(4-fluorophenyl)phenyl]piperazine and 2-(2,5-dioxo-4-imidazolidinyl)-1-ethanesulfonyl chloride (preparation given) in the presence Et3N in CH2C12 afforded II.

IT 459819-55-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459819-55-7 HCAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[2-(4-chlorophenyl)ethynyl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:736236 HCAPLUS
DOCUMENT NUMBER: 137:247696
TITLE: Preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors
INVENTOR(S): Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Zlatoidsky, Pavol
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074750	A1	20020926	WO 2002-SE475	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440632	A1	20020926	CA 2002-2440632	20020313

AU 2002237629	A1	20021003	AU 2002-237629		20020313
EE 200300439	A	20031215	EE 2003-439		20020313
EP 1370536	A1	20031217	EP 2002-704034		20020313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002008105	A	20040309	BR 2002-8105		20020313
CN 1509275	A	20040630	CN 2002-810041		20020313
HU 2004000206	A2	20040830	HU 2004-206		20020313
HU 2004000206	A3	20041028			
JP 2004527511	T	20040909	JP 2002-573759		20020313
EP 1676846	A2	20060705	EP 2006-8158		20020313
EP 1676846	A3	20060726			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 1962641	A	20070516	CN 2006-10106152		20020313
IN 2003MN00800	A	20050318	IN 2003-MN800		20030827
MX 2003PA08180	A	20031212	MX 2003-PA8180		20030910
NO 2003004025	A	20031113	NO 2003-4025		20030911
US 20040147573	A1	20040729	US 2003-471808		20030912
PRIORITY APPLN. INFO.:			SE 2001-902	A	20010315
			SE 2001-903	A	20010315
			CN 2002-810093	A3	20020313
			EP 2002-704031	A3	20020313
			WO 2002-SE475	W	20020313

OTHER SOURCE(S): MARPAT 137:247696

GI



AB The title compds. [I; X = NR1, O, S; B = C, CH, and is a point of attachment of one or more other functional groups or side chains; Y1, Y2 = O, S; R1 = H, alkyl, haloalkyl], useful in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes (no biol. data), were prepared E.g., a 4-step synthesis of II, starting with 4-(4-chlorophenyl)benzaldehyde, was given.

IT 459819-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 5-substituted imidazolidine-2,4-diones as metalloproteinase inhibitors)

RN 459819-55-7 HCAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[2-(4-chlorophenyl)ethynyl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:532117 HCAPLUS
DOCUMENT NUMBER: 137:247471
TITLE: C1-C5 Photochemical Cyclization of Enediynes
AUTHOR(S): Alabugin, Igor V.; Kovalenko, Serguei V.
CORPORATE SOURCE: Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL, 32306-4390, USA
SOURCE: Journal of the American Chemical Society (2002), 124(31), 9052-9053
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:247471
GI



AB Bis(tetrafluoropyridinylethynyl)benzenes I (R = R1 = H, Me; R = H, Cl; R1 = Cl, H) undergo photochem. activated cyclization of enediynes to provide indenes II as the major products in 2-22% yields. The cyclization of I (R = H; R1 = Cl) is regioselective, giving II (R = Cl; R1 = H) as the major product. The remainder of the mass balance in the photochem. cyclization of I to II was made up of radical addition products derived from I and 1,4-cyclohexadiene. The photochem. cyclizations of I to II operate by a mechanism different from that operating in the Bergmann cyclization of enediynes; the key step in this cyclization is photoinduced electron

transfer from 1,4-cyclohexadiene to I. The energies of the starting materials, transition states for cyclization, and radical products formed from the photochem. cyclizations of (Z)-3-hexen-1,5-diyne and 1,2-diethynylbenzene are calculated for both neutral radical and radical anion pathways. The crystal structure of II (R = R1 = Me) was determined by X-ray crystallog.

IT 459457-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and photochem. cyclization reactions of (tetrafluoropyridinylethynyl)benzenes to give indenes)

RN 459457-32-0 HCAPLUS

CN Pyridine, 4,4'-[(4-chloro-1,2-phenylene)di-2,1-ethynediyl]bis[2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:511159 HCAPLUS

DOCUMENT NUMBER: 131:157709

TITLE: Preparation of bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists

INVENTOR(S): Norman, Mark H.; Chen, Ning; Han, Nianhe; Liu, Longbin; Hurt, Clarence R.; Fotsch, Christopher H.; Jenkins, Tracy J.; Moreno, Ofir A.

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 469 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940091	A1	19990812	WO 1999-US2500	19990205

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,

KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6187777	B1	20010213	US 1999-246775	19990204
CA 2319275	A1	19990812	CA 1999-2319275	19990205
CA 2319275	C	20071016		
AU 9926590	A	19990823	AU 1999-26590	19990205
AU 747920	B2	20020530		
EP 1054887	A1	20001129	EP 1999-906756	19990205
EP 1054887	B1	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2003502272	T	20030121	JP 2000-530520	19990205
AT 323088	T	20060415	AT 1999-906756	19990205
PT 1054887	T	20060630	PT 1999-906756	19990205
ES 2257851	T3	20060801	ES 1999-906756	19990205
ZA 9900967	A	19990806	ZA 1999-967	19990208
MX 2000PA07662	A	20010219	MX 2000-PA7662	20000804
US 6583154	B1	20030624	US 2000-640263	20000816
PRIORITY APPLN. INFO.:			US 1998-73927P	P 19980206
			US 1998-73981P	P 19980206
			US 1998-93482P	P 19980720
			US 1998-93577P	P 19980720
			US 1999-246775	A 19990204
			WO 1999-US2500	W 19990205

OTHER SOURCE(S): MARPAT 131:157709

GI



I

AB Title compds.[I; R = H, CH3, (CH3)2CH, SCH3, CH3CH2, NH2, CF3, NHCOC6H5, cyclopropyl, CH2OH, (CH3)2CH2CH2, N(CH3)2, OCH3, NHCH3, NH(CH2)4NH2; R1 = NH, S, NCH3, O; R2 = H, COCH3, C6H5, CH3, CH3CH2; R3 = NH2, CH3, NHC6H5, N(CH2CH3)2, (CH3CH2)N(CH2)3CH3, (CH3)N(CH2)2NHCH3, N(CH3)CH(CH3)CH(Ph)OH, (CH3CH2)NCH2C(CH3):CH2, NHCH2CF3, NHCH2CH2C6H5, NH(CH2)3OCH2CH3, 4-ClC6H4, 4-CH3OC6H5, 2-thienyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 3-pyridyl; R4 = C6H5, 4-CH3C6H4, 4-ClC6H4, (CH3)3C, 4-FC6H4, 3-HOC6H4, 2-pyridyl, cyclohexyl, 2-furyl, 2-FC6H4 2-thienyl, 1-adamantyl, CH3, 4-CH3OC6H4; X = N, CH; etc.], pharmaceutical acceptable salts, ester, solvate, and N-oxide are prepared and tested as neuropeptide Y receptor antagonists in the modulation of feeding behavior, obesity, diabetes, cancer, inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions. Thus, the title compound I (R = CH3; R1 = NH; X = N; R2 = H; R3 = N(CH2CH3)2; R4 = C6H5) was prepared

IT 237435-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyridine and pyrrolopyrimidine derivs. as neuropeptide Y receptor antagonists)
RN 237435-20-0 HCAPLUS
CN 3-Pyridinamine, 4-chloro-2-[2-(4-fluorophenyl)ethynyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:148325 HCAPLUS
Correction of: 1999:64775
DOCUMENT NUMBER: 130:153580
Correction of: 130:124995
TITLE: Preparation of pyridine derivatives for treating disorders mediated full or in part by mGluR5
INVENTOR(S): Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Cosford, Nicholas David; Gasparini, Fabrizio; Heckendorn, Roland; Johnson, Edwin Carl; Kuhn, Rainer; Varney, Mark Andrew; Velicelebi, Gonul
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.h.; Sibia Neurosciences Inc.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902497	A2	19990121	WO 1998-EP4266	19980709
WO 9902497	A3	19990401		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 544448	B	20030801	TW 1998-87110887	19980706
CA 2295678	A1	19990121	CA 1998-2295678	19980709
AU 9889743	A	19990208	AU 1998-89743	19980709

AU 738973	B2	20011004			
EP 998459	A2	20000510	EP 1998-941308		19980709
EP 998459	B1	20080423			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY					
TR 200000059	T2	20000621	TR 2000-59		19980709
BR 9811685	A	20000919	BR 1998-11685		19980709
HU 2000004225	A2	20010528	HU 2000-4225		19980709
HU 2000004225	A3	20010628			
JP 2001509504	T	20010724	JP 2000-502025		19980709
JP 3481208	B2	20031222			
NZ 502210	A	20020726	NZ 1998-502210		19980709
RU 2203889	C2	20030510	RU 2000-102667		19980709
CN 1203060	C	20050525	CN 1998-807050		19980709
AT 393145	T	20080515	AT 1998-941308		19980709
ZA 9806137	A	19990122	ZA 1998-6137		19980710
NO 2000000124	A	20000302	NO 2000-124		20000110
MX 200000433	A	20010821	MX 2000-433		20000111
US 6656957	B1	20031202	US 2000-722803		20001127
PRIORITY APPLN. INFO.:			US 1997-890689	A	19970711
			US 1997-891691	A	19970711
			WO 1998-EP4266	W	19980709
			US 2000-462511	B1	20000224

OTHER SOURCE(S): MARPAT 130:153580

GI



I

AB The title compds. [I; R1 = H, lower alkyl, hydroxy-lower alkyl, etc.; R2 = H, lower alkyl, CO2H, etc.; R3 = H, lower alkyl, CO2H, etc.; R4 = H, lower alkyl, OH, etc.; X = an optionally halo-substituted lower alkenylene or alkynylene bonded via vicinal unsatd. carbon atoms or an azo group; R5 = (un)substituted aromatic or heteroarom.] and their salts, useful for treating disorders mediated full or in part by mGluR1 or mGluR5 (no data) such as epilepsy, cerebral ischemia, ischemic diseases of the eye, muscle spasms, convulsions, pain, acute, traumatic and chronic degenerative processes of the nervous system and psychiatric diseases, were prepared Thus, reaction of 2,6-dimethylpyridine with 3-cyanobenzaldehyde in Ac2O afforded I [R1 = Me; R2-R4 = H; X = CH:CH; R5 = 3-NCC6H4].

IT 219913-73-2P 219913-80-1P 219913-82-3P
219913-87-8P 219914-33-7P 219914-34-8P
219914-35-9P 219914-49-5P 219914-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridine derivs. for treating disorders mediated full or in part by mGluR5)

RN 219913-73-2 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 219913-80-1 HCAPLUS
CN 2-Pyridinecarboxylic acid, 6-[2-(3,5-dichlorophenyl)ethynyl]-5-[3-(dimethylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 219913-82-3 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-2-methyl- (CA INDEX NAME)



RN 219913-87-8 HCAPLUS
CN 3-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, ethyl ester (CA INDEX NAME)



RN 219914-33-7 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, ethyl ester (CA INDEX NAME)



RN 219914-34-8 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 219914-35-9 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl- (CA INDEX NAME)



RN 219914-49-5 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 219914-52-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)



L14 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:64775 HCAPLUS
DOCUMENT NUMBER: 130:124995
TITLE: Preparation of pyridine derivatives for treating disorders mediated full or in part by mGluR5
INVENTOR(S): Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Cosford, Nicholas David; Gasparini, Fabrizio; Heckendorn, Roland; Johnson, Edwin Carl; Kuhn, Rainer; Varney, Mark Andrew; Velicelebi, Gonul
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Sibia Neurosciences Inc.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902497 A2		19990121	WO 1998-EP4266	19980709
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1997-891691 19970711
US 1997-890689 19970711

OTHER SOURCE(S): MARPAT 130:124995
GI



I

AB The title compds. [I; R1 = H, lower alkyl, hydroxy-lower alkyl, etc.; R2 = H, lower alkyl, CO2H, etc.; R3 = H, lower alkyl, CO2H, etc.; R4 = H, lower alkyl, OH, etc.; X = an optionally halo-substituted lower alkenylene or alkynylene bonded via vicinal unsatd. carbon atoms or an azo group; R5 = (un)substituted aromatic or heteroarom.] and their salts, useful for treating disorders mediated full or in part by mGluR1 or mGluR5 (no data) such as epilepsy, cerebral ischemia, ischemic diseases of the eye, muscle spasms, convulsions, pain, acute, traumatic and chronic degenerative processes of the nervous system and psychiatric diseases, were prepared Thus, reaction of 2,6-dimethylpyridine with 3-cyanobenzaldehyde in Ac2O afforded I [R1 = Me; R2-R4 = H; X = CH:CH; R5 = 3-(NC)C6H5].

IT 219913-73-2P 219913-80-1P 219913-82-3P
219913-87-8P 219914-33-7P 219914-34-8P
219914-35-9P 219914-49-5P 219914-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridine derivs. for treating disorders mediated full or in part by mGluR5)

RN 219913-73-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 219913-80-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 6-[2-(3,5-dichlorophenyl)ethynyl]-5-[3-(dimethylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 219913-82-3 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-2-methyl- (CA INDEX NAME)



RN 219913-87-8 HCAPLUS
CN 3-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, ethyl ester (CA INDEX NAME)



RN 219914-33-7 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, ethyl ester (CA INDEX NAME)



RN 219914-34-8 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 219914-35-9 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[2-(3-fluorophenyl)ethynyl]-6-methyl- (CA INDEX NAME)



RN 219914-49-5 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 219914-52-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)



L14 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:513625 HCAPLUS
DOCUMENT NUMBER: 127:190650
ORIGINAL REFERENCE NO.: 127:36973a,36976a

TITLE: Preparation of dihydropyridines, pyridines, benzopyranones, and triazoloquinazolines for use as adenosine receptor antagonists

INVENTOR(S): Jacobson, Kenneth A.; Jiang, Ji-Long; Kim, Yong-Chul; Karton, Yishai; Van Rhee, Albert M.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727177	A2	19970731	WO 1997-US1252	19970129
WO 9727177	A3	19971113		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2244774	A1	19970731	CA 1997-2244774	19970129
CA 2244774	C	20061017		
AU 9722466	A	19970820	AU 1997-22466	19970129
AU 709190	B2	19990826		
EP 885192	A1	19981223	EP 1997-905627	19970129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000516910	T	20001219	JP 1997-527065	19970129
US 6066642	A	20000523	US 1998-117598	19981207
AU 9957171	A	20000217	AU 1999-57171	19991101
AU 755525	B2	20021212		

PRIORITY APPLN. INFO.:

US 1996-10737P	P	19960129
US 1996-21191P	P	19960703
WO 1997-US1252	W	19970129

OTHER SOURCE(S): MARPAT 127:190650

GI



I



II

AB Dihydropyridines I [R2 = alkyl, haloalkyl, phenyl; R3 = alkyl, alkoxycarbonyl, alkylthiocarbonyl, alkylaminocarbonyl, alkyloxy; R2R3 = ring with 2 - 4 methylene groups; R4 = alkyl, aryl, alkenyl, alkylamino, alkyloxy, alkynyl; R5 = alkyloxycarbonyl, aryl, alkylthio, hydroxy,

alkylamino; R6 = Ph, naphthyl], benzopyranones II [R1 = R3 = H, hydroxy, alkyloxy, alkylcarbonyloxy; R2 = H, hydroxy, alkyloxy, alkylcarbonyloxy, alkenyloxy; R4 = Ph, styryl, phenylbutadienyl, phenylacetylenyl, iminomethyl], as well as pyridines and triazoloquinazolines, were prepared for pharmaceutical uses which involve blocking adenosine receptors such as treatment of cancer, inflammation, and asthma. Thus, 3,5,7-trimethoxyflavone was prepared by methylation of galangin with di-Me sulfate and gave Ki values of 0.509 ± 0.049, 6.45 ± 1.48, and 1.21 ± 0.30 μM for A1, A2a, A3 receptors, resp., when tested for displacement of specific [3H]PIA binding in rat brain membranes.

IT 194346-98-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of dihydropyridines, pyridines, benzopyranones, and triazoloquinazolines for use as adenosine receptor antagonists)

RN 194346-98-0 HCAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[2-(4-amino-3-iodophenyl)ethynyl]-1,4-dihydro-2-methyl-6-phenyl-, 3-ethyl 5-(phenylmethyl) ester (CA INDEX NAME)



L14 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:321906 HCAPLUS
DOCUMENT NUMBER: 127:26242
ORIGINAL REFERENCE NO.: 127:4963a,4966a
TITLE: High-birefringence liquid crystal dopants
INVENTOR(S): Wand, Michael; Thurmes, William N.; More, Kundalika; Vohra, Rohini T.
PATENT ASSIGNEE(S): Displaytech, Inc., USA
SOURCE: U.S., 33 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5626792	A	19970506	US 1994-301121	19940906

PRIORITY APPLN. INFO.: US 1994-301121 19940906
OTHER SOURCE(S): MARPAT 127:26242
AB High-birefringence liquid crystal dopants for use in electrooptical devices

having the formula R1XCC.tplbond.CDT wherein C and D are aromatic ring systems each of which has one or two 5-member or 6-member carbon rings wherein one or two carbons of any ring in C or D can be substituted with a N, O or S atom and wherein any ring in C or D can be substituted with one or two halogen atoms; T is a halogen atom, a haloalkyl, haloalkoxy, vinylhalide or YR2 group where Y is a single bond, a double bond, a triple bond, COS, CS2, CH=CHCOS, CH=CHCSS or CH=CHCOO and R2 is an alkyl group having 3-20 carbon atoms; X is a single bond, a double bond, a triple bond, O, S or a ZQW group, where Q is a cyclohexane or cyclohexene ring in which one or two of the ring carbons can be replaced with an O atom or in which one or more of the ring carbons can be substituted with a halogen atom or a cyano group, Z is a single bond or an O or S atom and W is a single bond, CH2, C2H4 or CH2O; and R1 is alkyl having 3-20 carbon atoms in which one or more CH2 groups can be halogenated, two neighboring CH2 groups can be substituted with an epoxide group or one or more non-neighboring CH2 groups can be substituted with a double bond, a triple bond, an O or S atom, or a SiRaRb group where Ra and Rb are alkyl or alkenyl having 1-6 carbon atoms are disclosed. The high-birefringence dopants also possess UV stability, IR clarity and other properties that affect LC properties.

IT 190649-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and reaction in preparing high-birefringence liq crystal dopant for electrooptical display devices)

RN 190649-20-8 HCAPLUS

CN Pyridine, 5-bromo-2-[2-(4-bromophenyl)ethynyl]- (CA INDEX NAME)



L14 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:689831 HCAPLUS
DOCUMENT NUMBER: 121:289831
ORIGINAL REFERENCE NO.: 121:52746h,52747a
TITLE: Pyridine derivatives and liquid-crystal media and display devices containing them
INVENTOR(S): Poetsch, Eike; Plach, Herbert; Meyer, Volker; Waechtler, Andreas; Hittich, Reinhard
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4234089	A1	19940414	DE 1992-4234089	19921009

PRIORITY APPLN. INFO.: DE 1992-4234089 19921009
OTHER SOURCE(S): MARPAT 121:289831
GI



I

AB The compds. have the general formula I, where R = C1-15 alkyl or alkylene, unsubstituted or monosubstituted with CN, halogen, or CF3, in which ≥1 CH2 groups may be replaced by O, CO, COO, OCO, or OCOO; n = 0 or 1; Z = CH2CH2, CH:CH, or C.tplbond.C; L1,L2 = H or F; Q = CHF, OCHF, CF2, OCF2, C2F4, OC2F4, or a single bond; and Y = H, F, or Cl.

IT 159041-39-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of; in formation of pyridine derivs. for liquid-crystal media and display devices)

RN 159041-39-1 HCAPLUS

CN Pyridine, 5-bromo-2-[2-[3,5-difluoro-4-(trifluoromethoxy)phenyl]ethynyl]- (CA INDEX NAME)



L14 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:484524 HCAPLUS
DOCUMENT NUMBER: 119:84524
ORIGINAL REFERENCE NO.: 119:14943a,14946a
TITLE: Luminescence of europium(III) chelates with 4-(arylethynyl)pyridines as ligands
AUTHOR(S): Takalo, Harri; Hanninen, Elina; Kankare, Jouko
CORPORATE SOURCE: Cent. Biotechnol., Turku, SF-20521, Finland
SOURCE: Helvetica Chimica Acta (1993), 76(2), 877-83
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Some spectral properties and luminescence intensities of EuIII chelates with 15 4-(arylethynyl)pyridine-2,6-dicarboxylic acids and 11 2,2',2'',2'''-{[4-(arylethynyl)pyridine-2,6-diyl]bis(methylenenitrilo)}tetrakis(acetic acids) were measured both in H2O and EtOH solns. to develop suitable labels for time-resolved

luminescence-based bioaffinity assays. Several of the latter ligands and their Eu complexes were prepared for the 1st time. The substitution at the aryl group has a significant effect upon the observed luminescence intensities, excitation wavelengths, and decay consts. of the complexes. Moreover, the changes in the environment cause great variation in those properties of certain EuIII chelates.

IT 149826-91-5D, europium complex
RL: PRP (Properties)
(luminescence of)

RN 149826-91-5 HCAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[2-(3,5-dichloro-4-hydroxyphenyl)ethynyl]- (CA INDEX NAME)



IT 148886-04-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with europium)

RN 148886-04-8 HCAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[2-(3,5-dichloro-4-hydroxyphenyl)ethynyl]-, potassium salt (1:2) (CA INDEX NAME)



●2 K

IT 148902-83-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 148902-83-4 HCAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[2-(3,5-dichloro-4-hydroxyphenyl)ethynyl]-, 2,6-diethyl ester (CA INDEX NAME)



L14 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:196497 HCAPLUS
DOCUMENT NUMBER: 114:196497
ORIGINAL REFERENCE NO.: 114:32950h,32951a
TITLE: Optically active nicotinic acid ester derivatives as chiral smectic C liquid crystals
INVENTOR(S): Seto, Koji; Shimochizusho, Hiroshi
PATENT ASSIGNEE(S): Nitto Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02292260	A	19901203	JP 1989-115494	19890508

PRIORITY APPLN. INFO.: JP 1989-115494 19890508
GI



AB The title derivs. I (R = n-alkyl, alkoxy; R1 = asym. C-containing alkyl; A = 5,2-pyridinediyl, 2,5-pyridinediyl; X = H, halo; Y = C.tplbond.C, CH2CH2, OCO; Z = C.tplbond.C, CH2CH2, CO2; n = 0, 1) as liquid crystals are claimed. I have no other smectic phase below the chiral smectic C phase and are useful for ferroelec. compns. used in display devices, etc. Optically active 6-chloronicotinic acid 6-methyloctyl ester (preparation given) was treated with 4-Me(CH2)9OC6H4C.tplbond.CH to give I [R = decyloxy, R1 = (CH2)5CHMeEt, A = 5,2-pyridinediyl, X = H, Z = C.tplbond.C, n = 0], showing a chiral smectic C phase.

IT 133539-91-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

10598512

RN 133539-91-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[2-[4-(decyloxy)-3-fluorophenyl]ethynyl]-, 2-methylbutyl ester (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.22	536.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-21.60	-23.20

FILE 'CAOLD' ENTERED AT 18:31:22 ON 13 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- November 22, 2008 - removed from database clusters
- December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/CAplus. To learn more about the options available for transferring saved search queries and answer sets to CA/CAplus, contact your STN Service Center.

10598512

```
=> d his

     (FILE 'HOME' ENTERED AT 18:08:42 ON 13 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 18:08:51 ON 13 NOV 2008
L1               STRUCTURE UPLOADED
L2             1 S L1
L3            46 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 18:12:39 ON 13 NOV 2008
L4             2 S L3
L5             1 S L4 AND AGEJAS-CHICHARRO, F?/AU
L6             1 S L4 NOT L5
L7             0 S L6 AND DRESSMAN, B?/AU

     FILE 'CAOLD' ENTERED AT 18:13:40 ON 13 NOV 2008
L8             0 S L3

     FILE 'REGISTRY' ENTERED AT 18:24:19 ON 13 NOV 2008
L9               STRUCTURE UPLOADED
L10            1 S L9
L11           76 S L9 FULL

     FILE 'HCAPLUS' ENTERED AT 18:29:27 ON 13 NOV 2008
L12           27 S L11
L13            1 S L12 AND AGEJAS-CHICHARRO, F?/AU
L14           26 S L12 NOT L13
L15            0 S L14 AND DRESSMAN, B?/AU
L16            0 S L14 AND SANELICIANO, S?/AU
L17            0 S L14 AND HENRY, S?/AU
L18            0 S L14 AND PEREZ, J?/AU

     FILE 'CAOLD' ENTERED AT 18:31:22 ON 13 NOV 2008

=> s l11
L19            0 L11

=>
```

Updated Search